magnesium oxide
Approved
Jun 22, 1982
Magnesium oxide (MgO), or magnesia, is a white hygroscopic solid mineral that occurs naturally as periclase and is a source of magnesium (see also oxide). It has an empirical formula of MgO and consists of a lattice of Mg2+ ions and O2− ions held together by ionic bonding. Magnesium hydroxide forms in the presence of water (MgO + H2O → Mg(OH)2), but it can be reversed by heating it to remove moisture. — Wikipedia
Clinical trial activity
107 trials · 147 clinical orgs · 7 marketing orgs
Earliest trial started Jul 1, 1997 (NCT00120588)
Timeline
1980s
1990s
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2010s
- Jul 16, 2012
Ferring — NDA Secondary Org
- Nov 21, 2016
Par Pharmaceuticals — Marketing Organization
- Nov 21, 2016
Bristol-Myers Squibb — Marketing Organization
2020s
- Jul 18, 2022
Hetero Labs Ltd — Marketing Organization
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 4
- Adenocarcinoma · Phase 2
- Alcohol-Induced Disorders · Phase 4
- Alcohol Withdrawal Delirium · Phase 3
- Anesthesia, General · Phase 4
- Anesthesia, Intravenous · Phase 4
- Antioxidants · Phase 3
- Arthritis, Rheumatoid · Phase 2/Phase 3
- Asthma · Phase 2
- Atrial Premature Complexes · Phase 2
- Attention Deficit Disorder with Hyperactivity · Phase 2/Phase 3
- Bone Diseases · Phase 1
- Brain Ischemia · Phase 4
- Breast Neoplasms · Phase 2
- Cancer Survivors · Phase 2
- Cardiovascular Diseases · Phase 3
- Chronic Pain · Phase 1
- Colonic Neoplasms · Phase 4
- Colonoscopy · Phase 4
- Colorectal Neoplasms · Phase 4
- Constipation · Phase 4
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 3
- Critical Illness · Phase 4
- Diabetes Mellitus · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 3
- Diabetic Neuropathies · Phase 2
- Dialysis · Phase 2
- Endoscopy · Phase 4
- Endothelial Cells · Phase 4
- Euthyroid Sick Syndromes · Phase 4
- Febrile Neutropenia · Phase 2
- Fractures, Bone · Phase 3
- Fractures, Stress · Phase 3
- General Surgery · Phase 4
- Healthy Volunteers · Phase 4
- Hearing Loss, Noise-Induced · Phase 2
- Heart Diseases · Phase 3
- Heart Failure · Phase 3
- Heart Valve Diseases · Phase 3
- HIV Infections · Phase 1
- Hot Flashes · Phase 2
- Hyperphosphatemia · Phase 1
- Hypertension · Phase 4
- Hypokalemia · Phase 1/Phase 2
- Hyponatremia · Phase 1/Phase 2
- Intestine, Large · Phase 4
- Intracranial Hemorrhages · Phase 4
- Intubation · Phase 2
- Kidney Failure, Chronic · Phase 2
- Leukomalacia, Periventricular · Phase 4
- Liver Cirrhosis · Phase 4
- Liver Transplantation · Phase 4
- Magnesium Deficiency · Phase 4
- Multiple Sclerosis · Phase 1
- Myocardial Infarction · Phase 3
- Myocardial Ischemia · Phase 3
- Neoplasms · Phase 2
- Neurologic Manifestations · Phase 2
- Obesity · Phase 3
- Obstetric Labor, Premature · Phase 3
- Osteoarthritis · Phase 2
- Osteoporosis · Phase 1
- Oxidative Stress · Phase 2
- Pain · Phase 3
- Pancreatic Neoplasms · Phase 2
- Pancreatitis · Phase 2/Phase 3
- Post-Concussion Syndrome · Early Phase 1
- Postoperative Pain · Phase 4
- Prediabetic State · Phase 3
- Pregnancy · Phase 4
- Premature Birth · Phase 4
- Pseudoxanthoma Elasticum · Phase 2
- Quality of Life · Phase 4
- Renal Insufficiency, Chronic · Phase 2
- Reperfusion Injury · Phase 4
- Scoliosis · Phase 2
- Sleep-Wake Transition Disorders · Phase 4
- Sperm Injections, Intracytoplasmic · Phase 3
- Sprains and Strains · Phase 3
- Temporomandibular Joint Disorders · Phase 1/Phase 2
- Tendinopathy · Phase 3
- Tinnitus · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Vascular Diseases · Phase 3
- Wounds and Injuries · Phase 4
Mechanism of action
- Unspecified targetBuffer
buffer
Combination products
irrigating solution g
with citric acid, sodium carbonate
Also known as urologic g
prepopik
with sodium picosulfate, citric acid
Also known as clenpiq
Approval history
- approvedJun 22, 1982
Chemistry & pharmacology
SMILES
O=[Mg]- Mol. weight
- 40.3 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaMagnesium oxide ↗
- ChEMBLCHEMBL1200572 ↗
Also known as
- calcined magnesia
- calcined magnesia
- calcium magnesia
- e530
- e530
- magdose
- magmitt
- magmitt
- magnesia
- magnesia
- magnesium
- magnesium
- magnesium
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide
- magnesium oxide monohydrate
- mag ox
- mag-ox 400
- magstar
- oromag 160
- oximag
- uro-mag
- uro-mag
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07173855 | Phase 4 | Nov 25, 2025 | Scarborough General Hospital |
| NCT06915701 | Phase 2/Phase 3 (Phase 3) | Apr 28, 2025 | University of Guadalajara |
| NCT06580366 | Phase 4 | Aug 22, 2024 | Hitit University |
| NCT05774015 | N/A | Sep 25, 2023 | Karolinska Institute, Sultan Qaboos University |
| NCT06950138 | Phase 3 | Jan 3, 2023 | Government of Mexico |
| NCT05148494 | Phase 4 | Feb 1, 2022 | Government of Canada |
| NCT04161599 | Phase 4 | Feb 29, 2020 | Universidad Autonoma de Barcelona |
| NCT04483037 | Phase 4 | Jan 1, 2020 | Changhua Christian Hospital |
| NCT04113382 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Ferring |
| NCT04033250 | N/A | Aug 31, 2019 | Technion University |
| NCT03898336 | N/A | Jul 1, 2019 | Radboud University, University of Groningen, University of Heidelberg |
| NCT03840226 | Phase 3 | May 1, 2019 | Naveh Pharma LTD, Tel Aviv University |
| NCT03593252 | N/A | Sep 1, 2018 | McMaster University |
| NCT04259606 | N/A | Aug 17, 2018 | University of Guadalajara |
| NCT04216836 | N/A | Jun 28, 2018 | Beijing Sport University, Coventry University, University of Rochester |
| NCT03632590 | N/A | Mar 27, 2018 | Nedmag, University of Groningen |
| NCT03449693 | Phase 2 | Oct 19, 2017 | Government of Mexico, National Autonomous University of Mexico, National Polytechnic Institute, Mexico |
| NCT03475693 | Early Phase 1 (Phase 1) | Sep 1, 2017 | Lakeland Regional Medical Center, Michigan State University |
| NCT03132701 | N/A | Jun 7, 2017 | Seoul National University |
| NCT03190044 | N/A | Jun 6, 2017 | University of Roma La Sapienza |
Organizations
Research & Development (147)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Mexico | Government | 6 | 5 | 3 | 2010 |
| University of Guadalajara | Academic/Hospital | 4 | 3 | 3 | 2003 |
| Tel Aviv University | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Ain Shams University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Ferring | For profit | 2 | 2 | 2 | 2017 |
| Government of France | Government | 2 | 0 | 2 | 1997 |
| Isfahan University | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 2 | 2011 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 1 | 2 | 1998 |
| National University of Ireland | Academic/Hospital | 2 | 1 | 2 | 2011 |
| Pennsylvania State University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Radboud University | Academic/Hospital | 2 | 2 | 1 | 2003 |
| Technion University | Academic/Hospital | 2 | 2 | 2 | 2013 |
| The Canadian College of Naturopathic Medicine | Academic/Hospital | 2 | 1 | 2 | 2008 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 2 | 2007 |
| University of Groningen | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of Toronto | Academic/Hospital | 2 | 1 | 2 | 2008 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| AGUNCO Obstetrics and Gynecology Centre | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Alberta Heritage Foundation for Medical Research | Academic/Hospital | 1 | 0 | 1 | 2011 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Baxalta | For profit | NDA2 | Jun 22, 1982 |
| Baxter | For profit | NDA2 | Jun 22, 1982 |
| Baxter | For profit | NDA | Jun 22, 1982 |
| Bristol-Myers Squibb | For profit | MKTG | Nov 21, 2016 |
| Ferring | For profit | NDA2 | Jul 16, 2012 |
| Hetero Labs Ltd | For profit | MKTG | Jul 18, 2022 |
| Hospira | For profit | NDA2 | Mar 15, 1984 |
| Par Pharmaceuticals | For profit | MKTG | Nov 21, 2016 |